VIGL vs. VYGR, EDIT, OCGN, TCRX, ALLO, FATE, JSPR, AURA, TRML, and STRO
Should you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include Voyager Therapeutics (VYGR), Editas Medicine (EDIT), Ocugen (OCGN), TScan Therapeutics (TCRX), Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), Jasper Therapeutics (JSPR), Aura Biosciences (AURA), Tourmaline Bio (TRML), and Sutro Biopharma (STRO). These companies are all part of the "biological products, except diagnostic" industry.
Voyager Therapeutics (NASDAQ:VYGR) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
Vigil Neuroscience has a net margin of 0.00% compared to Vigil Neuroscience's net margin of -2.56%. Vigil Neuroscience's return on equity of -1.28% beat Voyager Therapeutics' return on equity.
In the previous week, Vigil Neuroscience had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 4 mentions for Vigil Neuroscience and 3 mentions for Voyager Therapeutics. Vigil Neuroscience's average media sentiment score of 1.66 beat Voyager Therapeutics' score of 1.15 indicating that Voyager Therapeutics is being referred to more favorably in the media.
Voyager Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.
Voyager Therapeutics received 361 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 75.00% of users gave Vigil Neuroscience an outperform vote while only 67.32% of users gave Voyager Therapeutics an outperform vote.
Voyager Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 116.35%. Vigil Neuroscience has a consensus target price of $17.20, suggesting a potential upside of 419.64%. Given Voyager Therapeutics' higher probable upside, analysts clearly believe Vigil Neuroscience is more favorable than Voyager Therapeutics.
48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by insiders. Comparatively, 33.0% of Vigil Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Voyager Therapeutics has higher revenue and earnings than Vigil Neuroscience. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.
Summary
Voyager Therapeutics beats Vigil Neuroscience on 9 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding VIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vigil Neuroscience Competitors List
Related Companies and Tools
